Drugnews

What were Leqvio’s Q3 2026 sales and Novartis’s peak-sales outlook?

In Drugnews’s November 3, 2026 analysis of Novartis’s October 27 results, Leqvio (inclisiran) generated US$506 million in Q3 2026 sales, up 64% from US$308 million a year earlier. The article reports management’s peak-sales outlook at more than US$4 billion. That outlook is a forecast, and ORION-4 cardiovascular outcome results are a separate evidentiary question.

Updated

Leqvio: reported quarter versus future outlook
MeasureReported resultBasis
Q3 2026 revenueUS$506 millionReported sales
Year-over-year growth64%As reported in the original analysis
Prior-year quarterUS$308 millionComparable sales period
Management peak-sales outlookMore than US$4 billionForward-looking; not booked revenue

The original article’s prediction of ORION-4 success is an editorial forecast. It is not treated here as a completed trial result or a new approved indication.

Sources

Read the full analysis

Entresto Sinks 38%; Novartis Bets on Leqvio — 2026-11-03